KPTI

Selinexor

CRC (combination with pembrolizumab) and NSCLC (combination with docetaxel) | XPORT-STP-027

Phase 1

Exp Date

TBD

Amp Volatility Score

Catalyst Info & Data Links

Potential Catalyst Events

  • TBA


Clinical Trial

  • NCT04256707: Bioequivalence and the Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)



Prior Data Links


HC updated 5/22/20

MECHANISM OF ACTION/RATIONALE

  • Nuclear export inhibitor

  • Inhibits XPO1 (see slide 5), which is believed to impact tumor cells in 3 ways

1. Increases nuclear levels and activation of tumor suppressor proteins
2. Traps oncoprotein mRNA in the nucleus leading to reduced oncoprotein levels
3. Retains activated glucocorticoid receptor in the nucleus

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon